114 related articles for article (PubMed ID: 7691393)
21. Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer.
Maffezzini M; Bossi A; Collette L
Eur Urol; 2007 Mar; 51(3):605-13; discussion 613. PubMed ID: 17113217
[TBL] [Abstract][Full Text] [Related]
22. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
Duchesne GM; Woo HH; Bassett JK; Bowe SJ; D'Este C; Frydenberg M; King M; Ledwich L; Loblaw A; Malone S; Millar J; Milne R; Smith RG; Spry N; Stockler M; Syme RA; Tai KH; Turner S
Lancet Oncol; 2016 Jun; 17(6):727-737. PubMed ID: 27155740
[TBL] [Abstract][Full Text] [Related]
23. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality.
Efstathiou JA; Chen MH; Catalona WJ; McLeod DG; Carroll PR; Moul JW; Roehl KA; D'Amico AV
Urology; 2006 Aug; 68(2):342-7. PubMed ID: 16904449
[TBL] [Abstract][Full Text] [Related]
24. Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen era.
D'Amico AV; Cote K; Loffredo M; Renshaw AA; Schultz D
J Urol; 2003 Dec; 170(6 Pt 2):S42-6; discussion S46-7. PubMed ID: 14610409
[TBL] [Abstract][Full Text] [Related]
25. Salvage radiation in men after prostate-specific antigen failure and the risk of death.
Cotter SE; Chen MH; Moul JW; Lee WR; Koontz BF; Anscher MS; Robertson CN; Walther PJ; Polascik TJ; D'Amico AV
Cancer; 2011 Sep; 117(17):3925-32. PubMed ID: 21437885
[TBL] [Abstract][Full Text] [Related]
26. Radiotherapy for localized prostate carcinoma. The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen.
Crook JM; Bahadur YA; Bociek RG; Perry GA; Robertson SJ; Esche BA
Cancer; 1997 Jan; 79(2):328-36. PubMed ID: 9010106
[TBL] [Abstract][Full Text] [Related]
27. Localized carcinoma of the prostate (stages T1B, T1C, T2, and T3). Review of management with external beam radiation therapy.
Perez CA; Hanks GE; Leibel SA; Zietman AL; Fuks Z; Lee WR
Cancer; 1993 Dec; 72(11):3156-73. PubMed ID: 7694785
[TBL] [Abstract][Full Text] [Related]
28. Active surveillance for prostate cancer: for whom?
Klotz L
J Clin Oncol; 2005 Nov; 23(32):8165-9. PubMed ID: 16278468
[TBL] [Abstract][Full Text] [Related]
29. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations.
Lee WR; Hanks GE; Hanlon A
J Clin Oncol; 1997 Jan; 15(1):230-8. PubMed ID: 8996147
[TBL] [Abstract][Full Text] [Related]
30. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
31. Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer.
Klotz L
Eur Urol; 2005 Jan; 47(1):16-21. PubMed ID: 15582244
[TBL] [Abstract][Full Text] [Related]
32. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
Zhou P; Chen MH; McLeod D; Carroll PR; Moul JW; D'Amico AV
J Clin Oncol; 2005 Oct; 23(28):6992-8. PubMed ID: 16192586
[TBL] [Abstract][Full Text] [Related]
33. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
Ray ME; Thames HD; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Shipley WU; Zelefsky MJ; Zietman AL; Kuban DA
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1140-50. PubMed ID: 16198506
[TBL] [Abstract][Full Text] [Related]
34. Predictors of metastatic disease after prostate brachytherapy.
Forsythe K; Burri R; Stone N; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):645-52. PubMed ID: 22137025
[TBL] [Abstract][Full Text] [Related]
35. Predictors of mortality after prostate-specific antigen failure.
D'Amico AV; Kantoff P; Loffredo M; Renshaw AA; Loffredo B; Chen MH
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):656-60. PubMed ID: 16682147
[TBL] [Abstract][Full Text] [Related]
36. PSA doubling time kinetics during prostate cancer biochemical relapse after external beam radiation therapy.
Bates AT; Pickles T; Paltiel C
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):148-53. PubMed ID: 15850915
[TBL] [Abstract][Full Text] [Related]
37. Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy.
Pinover WH; Horwitz EM; Hanlon AL; Uzzo RG; Hanks GE
Cancer; 2003 Feb; 97(4):1127-33. PubMed ID: 12569615
[TBL] [Abstract][Full Text] [Related]
38. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer.
Ritter MA; Messing EM; Shanahan TG; Potts S; Chappell RJ; Kinsella TJ
J Clin Oncol; 1992 Aug; 10(8):1208-17. PubMed ID: 1378886
[TBL] [Abstract][Full Text] [Related]
39. Factors Predicting the Off-treatment Duration in Patients with Prostate Cancer Receiving Degarelix as Intermittent Androgen Deprivation Therapy.
Abrahamsson PA; Boccon-Gibod L; Morote J; de Jong IJ; Malmberg A; Neijber A; Albers P
Eur Urol Focus; 2017 Oct; 3(4-5):470-479. PubMed ID: 28753747
[TBL] [Abstract][Full Text] [Related]
40. Active surveillance with selective delayed intervention for favorable risk prostate cancer.
Klotz L
Urol Oncol; 2006; 24(1):46-50. PubMed ID: 16414494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
